Inhibition of DNA repair as a mechanism of enhanced radioresponse of head and neck carcinoma cells by a selective cyclooxygenase-2 inhibitor, celecoxib

International Journal of Radiation Oncology Biology Physics

Volumn 63, Issue 2, 2005, Pages 520-528

  Raju, Uma ^a   Ariga, Hisanori ^c   Dittmann, Klaus ^d   Nakata, Eiko ^e   Ang, Kian K ^b   Milas, Luka ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c Miyagi Cancer Center   (Japan)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Celecoxib; Inhibition of DNA repair; Ku70; NF B; Radiosensitization

Indexed keywords

BIOASSAY; CARCINOGENS; CELL CULTURE; ELECTROPHORESIS; ENZYME INHIBITION; TUMORS;

CELECOXIB; INHIBITION OF DNA REPAIR; KU70; NFΚB; RADIOSENSITIZATION;

DNA;

CELECOXIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KU ANTIGEN;

ARTICLE; CARCINOMA CELL; CELL SURVIVAL; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA BINDING; DNA PROTEIN COMPLEX; DNA REPAIR; DOWN REGULATION; DRUG EFFECT; ENZYMATIC ASSAY; GEL MOBILITY SHIFT ASSAY; GROWTH INHIBITION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; RADIATION RESPONSE; RADIOSENSITIZATION; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; CYCLOOXYGENASE INHIBITORS; DNA; DNA REPAIR; DNA-ACTIVATED PROTEIN KINASE; DNA-BINDING PROTEINS; DOWN-REGULATION; HEAD AND NECK NEOPLASMS; HUMANS; NF-KAPPA B; NUCLEAR PROTEINS; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; RADIATION-SENSITIZING AGENTS; SULFONAMIDES;

EID: 24944579985     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2005.06.007     Document Type: Article

References (45)

1. J.R. Vane, J.A. Mitchell, I. Appleton Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation Proc Natl Acad Sci U S A 91 1994 2046 2050
2. D.T. Lin, K. Subbaramaiah, J.P. Shah Cyclooxygenase-2 A novel molecular target for the prevention and treatment of head and neck cancer Head Neck 24 2002 792 799
3. Z. Liao, L. Milas COX-2 and its inhibition as a molecular target in the prevention and treatment of lung cancer Expert Rev Anticancer Ther 4 2004 543 560
4. T. Koga, K. Shibahara, A. Kabashima Overexpression of cyclooxygenase-2 and tumor angiogenesis in human gastric cancer Hepatogastroenterology 51 2004 1626 1630
5. H. Murata, S. Kawano, S. Tsuji Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma Am J Gastroenterol 94 1999 451 455
6. F.R. Khuri, H. Wu, J.J. Lee Cyclooxygenase-2 overexpression is a marker of poor prognosis in Stage I non-small cell lung cancer Clin Cancer Res 7 2001 861 867
7. D.K. Gaffney, J. Holden, M. Davis Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy Int J Radiat Oncol Biol Phys 49 2001 1213 1217
8. D.S. Dandekar, M. Lopez, R.I. Carey Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells Int J Cancer 115 2005 484 492
9. L. Milas Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse Semin Radiat Oncol 11 2001 290 299
10. L. Milas, K.A. Mason, C.H. Crane Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme Oncology 17 2003 15 24
11. T.W. Davis, J.M. O'Neal, M.D. Pagel Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature Cancer Res 64 2004 279 285
12. T. Shah, S. Ryu, H.J. Lee Pronounced radiosensitization of cultured human cancer cells by COX inhibitor under acidic microenvironment Int J Radiat Oncol Biol Phys 53 2002 1314 1318
13. H. Pyo, H. Choy, G.P. Amorino A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2 Clin Cancer Res 7 2001 2998 3005
14. K. Kishi, S. Petersen, C. Petersen Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor Cancer Res 60 2000 1326 1331
15. E. Nakata, K.A. Mason, N. Hunter Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors Int J Radiat Oncol Biol Phys 58 2004 369 375
16. U. Raju, E. Nakata, P. Yang In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme Mechanistic considerations Int J Radiat Oncol Biol Phys 54 2002 886 894
17. A.L. Hsu, T.T. Ching, D.S. Wang The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2 J Biol Chem 275 2000 11397 11403
18. C.P. Raut, S. Nawrocki, L.M. Lashinger Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts Cancer Biol Ther 3 2004 1217 1224
19. H.E. Zeytin, A.C. Patel, C.J. Rogers Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice Cancer Res 64 2004 3668 3678
20. J.L. Masferrer, K.M. Leahy, A.T. Koki Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors Cancer Res 60 2000 1306 1311
21. J.A. Han, J.-I. Kim, P.P. Ongusaha p53-mediated induction of COX-2 counteracts p53- or genotoxic stress-induced apoptosis EMBO J 21 2002 5635 5644
22. B. Fertil, E.P. Malaise Inherent cellular radiosensitivity as a basic concept for human tumor radiotherapy Int J Radiat Oncol Biol Phys 7 1981 621 629
23. U. Raju, G.J. Gumin, F. Noel IκBα degradation is not a requirement for the X-ray-induced activation of nuclear factor κB in normal rat astrocytes and human brain tumour cells Int J Radiat Biol 74 1998 617 624
24. K. Dittmann, P. Virsik-Köpp, C. Mayer Bowman-Birk protease inhibitor activates DNA-dependent protein kinase and reduces formation of radiation-induced dicentric chromosomes Int J Radiat Biol 79 2003 801 808
25. U. Raju, R. Lu, F. Noel Failure of a second X-ray dose to activate nuclear factor kappaB in normal rat astrocytes J Biol Chem 272 1997 24624 24630
26. S.H. Kim, D. Kim, J.S. Han Ku autoantigen affects the susceptibility to anticancer drugs Cancer Res 59 1999 4012 4017
27. M. Yaneva, T. Kowalewski, M.R. Lieber Interaction of DNA-dependent protein kinase with DNA and with Ku Biochemical and atomic-force microscopy studies EMBO J 16 1997 5098 5112
28. J.W. Lim, H. Kim, K.H. Kim Expression of Ku70 and Ku80 mediated by NFκB and cyclooxygenase-2 is related to proliferation of human gastric cancer cells J Biol Chem 277 2002 46093 46100
29. H. Choy, L. Milas Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors A rational advance? J Natl Cancer Inst 95 2003 1440 1452
30. C. Petersen, S. Petersen, L. Milas Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor Clin Cancer Res 6 2000 2513 2520
31. M. Li, X. Wu, X. Xu Induction of apoptosis by cyclo-oxygenase-2 inhibitor NS398 through a cytochrome c-dependent pathway in esophageal cancer cells Int J Cancer 93 2001 218 223
32. S. Pucci, P. Mazzarelli, C. Rabitti Tumor specific modulation of KU70/80 DNA binding activity in breast and bladder human tumor biopsies Oncogene 20 2001 739 747
33. T.J. Gaymes, G.J. Mufti, F.V. Rassool Myeloid leukemias have increased activity of the nonhomologous end-joining pathways and concomitant DNA misrepair that is dependent on the Ku70/86 heterodimer Cancer Res 62 2002 2791 2797
34. L. Maggiorella, E. Deutsch, V. Frascogna Enhancement of radiation response by roscovitine in human breast carcinoma in vitro and in vivo Cancer Res 63 2003 2513 2517
35. M. Christmann, M.T. Tomicic, W.P. Roos Mechanisms of human DNA repair An update Toxicol 193 2003 3 34
36. M.R. Lieber, Y. Ma, U. Pannicke Mechanism and regulation of human non-homologous DNA end-joining Nat Rev Mol Cell Biol 4 2003 712 720
37. A. Garg, B.B. Aggarwal Nuclear transcription factor-κB as a target for cancer drug development Leukemia 16 2002 1053 1068
38. A.S. Baldwin Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB J Clin Invest 107 2001 241 246
39. T. Tamatani, M. Azuma, Y. Ashida Enhanced radiosensitization and chemosensitization in NF-kappaB-suppressed human oral cancer cells via the inhibition of gamma-irradiation- and 5-FU-induced production of IL-6 and IL-8 Int J Cancer 108 2004 912 921
40. S. Shishodia, B.B. Aggarwal Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaB alpha kinase in human non-small cell lung carcinoma Correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9 Cancer Res 64 2004 5004 5012
41. B. Wen, E. Deutsch, P. Eschwege Cyclooxygenase-2 inhibitor NS398 enhances antitumor effect of irradiation on hormone refractory human prostate carcinoma cells J Urol 170 2003 2036 2039
42. N. Yamagishi, J. Miyakoshi, H. Takebe Enhanced radiosensitivity by inhibition of nuclear factor κB activation in human malignant glioma cells Int J Radiat Biol 72 1997 157 162
43. J.S. Russell, U. Raju, G.J. Gumin Inhibition of radiation-induced nuclear factor-kappaB activation by an anti-Ras single-chain antibody fragment Lack of involvement in radiosensitization Cancer Res 62 2002 2318 2326
44. S. Shishodia, D. Koul, B.B. Aggarwal Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-κB activation through inhibition of activation of IκBα kinase and Akt in human non-small cell lung carcinoma Correlation with suppression of COX-2 synthesis J Immunol 173 2004 2011 2022
45. B.F. El-Rayes, S. Ali, F.H. Sarkar Cyclooxygenase-2 dependent and -independent effects of celecoxib in pancreatic cancer cell lines Mol Cancer Ther 3 2004 1421 1426